24/7 Market News Snapshot 02 June, 2025 – Kura Oncology, Inc. (NASDAQ:KURA)

June 2, 2025

DENVER, Colo., 02 June, 2025 (www.247marketnews.com) – (NASDAQ:KURA) are discussed in this article.
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. have announced promising pivotal results from the KOMET-001 Phase 2 trial of ziftomenib, an investigational oral menin inhibitor targeting patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The findings, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, show a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% among heavily pretreated patients. Furthermore, the trial highlighted a notable 63% minimal residual disease (MRD)-negative rate among those who responded, underscoring the potential impact of this therapy.

The efficacy of ziftomenib was consistently observed across various patient subgroups, offering renewed hope for individuals facing a disease with limited treatment options. “What we have seen in the KOMET-001 trial is highly encouraging,” stated Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology. “NPM1 mutations are prevalent in AML, and with no FDA-approved therapies currently available for this patient population, we are committed to supporting the FDA’s review of the ziftomenib New Drug Application, targeting a decision by November 30, 2025.”

In terms of safety, ziftomenib demonstrated a favorable profile, with minimal myelosuppression and a low treatment discontinuation rate due to adverse events. Importantly, there were no significant concerns regarding QTc prolongation, which further validates its potential as a safe treatment alternative.

Kura and Kyowa Kirin are dedicated to expediting the development of ziftomenib in response to the urgent need for effective therapies in R/R NPM1-mutant AML. To further discuss these significant results, the companies will host a virtual investor event, reaffirming their commitment to advancing treatment options for patients confronting challenging prognoses in the field of hematologic malignancies. This collaborative initiative not only strengthens the potential for ziftomenib but also aims to bring hope to those affected by this serious condition.

Related news for (KURA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.